OBJECTIVE-The link between diabetes and prostate cancer is rarely studied in Asians.
T he association between diabetes and prostate cancer has been inconsistently reported, even though two meta-analyses suggested that diabetic patients have a lower risk of prostate cancer of 9% (1) and 16% (2), respectively.
While the two meta-analyses were examined, many studies were case-control and only three focused on the follow-up of cohorts of diabetic patients (3) (4) (5) . Among the three cohorts, the cases of prostate cancer were 9 (3), 498 (4), and 2,455 (5), respectively; and only the last (5) showed a significant 9% risk reduction in diabetic patients. Except for the first study being conducted in residents with diabetes in Rochester, Minnesota (3), the diabetic patients in the other two were from hospitalized patients in Denmark (4) and Sweden (5), respectively. The meta-analyses have limitations including a mixture of case-control and cohort designs, a mixture of incident and dead cases, a small number of prostate cancer in most studies, and different sources of subjects with potential selection bias. Although the contamination of type 1 diabetes is possibly minimal because .90% of overall patients have type 2 diabetes, residual confounding could not be excluded if the two types of diabetes are not differentiated.
Although some recent studies still suggested a lower risk of prostate cancer in diabetic patients including Caucasians (6,7), Iranians (8) , Israelis (9) , African Americans, Native Hawaiians, and Japanese Americans (6) , the lower risk in African Americans and Native Hawaiians (6) was not significant. Two Japanese studies did not find any significant association (10, 11) . The Ohsaki Cohort Study suggested that diabetes was not predictive for total prostate cancer, but diabetic patients did show a higher risk of advanced cancer (11) .
Because diabetic patients are prone to develop cancer involving pancreas, liver, breast, colorectum, bladder, and endometrium (12) (13) (14) (15) and the protective effect of diabetes on prostate cancer requires confirmation, this study evaluated the possible link between diabetes and prostate cancer, and the potential risk factors, by using the reimbursement database of the National Health Insurance (NHI) in Taiwan. (17) . Linear regression evaluated whether the trends changed significantly, where the incidence was the dependent and the calendar year the independent variable.
RESEARCH DESIGN AND METHODS

Study population
The age-specific cumulative incidences from 2003 to 2005 in diabetic and nondiabetic men were calculated for all ages and age 40-64, 65-74, and $75 years. The numerator was the number of patients with a first diagnosis of prostate cancer within [2003] [2004] [2005] ; and the denominator was the number of insurants in that specific age. The risk ratio between diabetic and nondiabetic men was calculated, and the 95% CI was estimated by Taylor series approximation (18) . To minimize the possibility that diabetes might be caused by prostate cancer during a different period, several lag time sensitivity analyses were performed by excluding patients with diabetes duration of ,1, ,3, and ,5 years.
In Taiwan, the National Health Research Institute recommends yearly screening of prostate cancer by digital rectal examination and prostate-specific antigen (PSA) determination for men aged $50 years or $45 years for those with a family history. The PSA cutoff is set at 4.0 ng/mL. If either examination is abnormal, prostate biopsy guided by transrectal ultrasonography is recommended. The cancer detection rate under this guideline was much lower in Taiwan (0.96-1.3%) than in the Western countries (3-5%); and population-based PSA Analyses were conducted using SAS statistical software, version 9.1 (SAS Institute, Cary, NC). Data were expressed as mean (SD) for continuous variables or number (%) for categorical variables. P , 0.05 was considered as statistically significant. Figure 2 shows the crude and age-standardized incidence trends in the general population. Both are increasing significantly (P , 0.0001). Table 1 shows the 3-year cumulative incidences and the risk ratios between the diabetic and nondiabetic men in different ages. The cumulative incidence markedly increased with age in either the diabetic or nondiabetic men. Risk ratio analysis showed that diabetic patients had a higher risk than nondiabetic men in all age groups. However, divergent associations with regard to age were noted: those in the youngest age of 40-64 years had the highest risk ratio, followed by those in the oldest of $75 years, and those aged 65-74 years had the lowest risk ratio.
RESULTS-
Diabetic patients did show a higher frequency in the use of PSA test in either the analysis for all ages or for age $40 years (Table 2) . Table 3 shows the results of the logistic regressions. The results were similar in models without (model I) or with (model II) PSA as an additional independent variable. In model II only the ORs for the different subgroups of diabetes duration and PSA test are shown. Age was a remarkable risk factor, and diabetes duration showed a nonlinear increase in the risk. Nephropathy, ischemic heart disease, dyslipidemia, living region, and occupation were significant, whereas chronic obstructive pulmonary disease was borderline significant. None of the medications was significant.
CONCLUSIONS-The trends of prostate cancer were increasing significantly in 1995-2006 (Fig. 2) , and diabetes was associated with an increased risk at any duration (Tables 1 and 3) , with the highest risk ratio observed in the youngest age of 40-64 years (Table 1) .
Although some recent studies still favored a protective effect of diabetes in Caucasians (6,7), a recent populationbased case-control study in the US concluded that diabetes was not associated with prostate cancer (OR = 0.98, 95% CI: 0.76-1.27) and that the protective effect of diabetes might be because of a confounding of a mixture with type 1 diabetes (20) . In the current study, patients with type 1 diabetes were excluded and its confounding is minimal.
Diabetes was unlikely caused by prostate cancer, because the association was consistent in different analyses (Table 1) . Diabetes diagnosed 5 years before prostate cancer can hardly be a consequence of the carcinogenic process. Another possibility for an increased incidence in the diabetic patients is because of screening bias (Table 2) . However, our analysis did not support such a possibility because the conclusions remained the same when PSA test was also included in the logistic analyses (model II of Table 3 ).
Heterogeneity may exist in the association between diabetes and prostate cancer. Some suggested that recent-onset diabetes may increase, but long-standing diabetes might reduce the risk (21) . In the current study, although prostate cancer risk increased with increasing diabetes duration in unadjusted models (data not shown), the adjusted models showed that the highest risk was observed at diabetes duration of 1-3 years and then declined gradually (Table 3) . Recently serum creatinine is shown to be significantly predictive for prostate cancer risk (22) . Our finding of a significantly higher risk of 27% in patients with nephropathy (Table  3) confirmed such an observation. Some suggested that patients with more severe diabetes might have lower level of PSA and lower risk of prostate cancer (23) . However, the current study showing a higher risk of prostate cancer associated with nephropathy, ischemic heart disease, and dyslipidemia (Table 3) argued against a simple scenario. With increasing duration and severity of diabetes, chronic complications may set in and interfere with the association between diabetes and prostate cancer. Some suggested that diabetes might only convey a higher risk of more advanced prostate cancer (11, 24) . However, we did not have sufficient information for analysis.
It is interesting to observe an effect modification by age with the highest risk ratio observed at the youngest age of 40-64 years (Table 1 ). One explanation is that a higher mortality from other causes in the older diabetic patients before the development of prostate cancer may obscure the relationship, as opposed to the youngest age group who might have been exposed to inflammatory and carcinogenic effects of diabetes for a longer period of time. Such a relationship simply might not have been captured by casecontrol designs.
Some commonly used medications did not affect the risk (Table 3) . However, geographical distribution and socioeconomic status, as indicated by living region and occupation, respectively, did significantly impact the risk (Table 3) . People living in metropolitan Taipei Tseng region had the highest risk, and the risk seemed to decline gradually with lesser urbanization as shown from the ORs, much deviating from unity from Northern to Central, Southern, and Kao-Ping and Eastern region (Table 3) . People with a higher socioeconomic status as indicated by occupation I also suffered from a higher risk (Table 3 ). The reasons for such discrepancy with regard to geographical distribution and socioeconomic status await further exploration.
This study has several strengths. It is population based with a large nationally representative sample. The database included outpatients and inpatients, and we caught the diagnoses from both sources. Cancer is considered as a severe morbidity by the NHI, and most medical copayments can be waived. Therefore the detection rate would not tend to differ among different social classes. The use of medical record also reduced the potential bias related to self-reporting. Limitations included a lack of actual measurement of confounders such as obesity, smoking, alcohol drinking, family history, lifestyle, diet, hormones, and genetic parameters. In addition, we did not have biochemical data for evaluating their impact. Finally, the follow-up interval is probably too short to plausibly account for the likely induction time needed between the onset of diabetes and the biological changes leading to prostate cancer.
In summary, this study shows an increasing trend of prostate cancer in Taiwan and a link between diabetes and prostate cancer, which is more remarkable in the age of 40-64 years. Therefore, the observation that diabetes confers a lower risk of prostate cancer might not be universal. Insulin or other oral antidiabetic agents are not, but nephropathy, ischemic heart disease, and dyslipidemia are significantly associated with prostate cancer. The association between prostate cancer and these comorbidities suggests a more complicated scenario in the link between prostate cancer and diabetes at different disease stages. Given that the population is aging, the incidence of prostate cancer is increasing, and the incidence of type 2 diabetes is also increasing (25) . The impact of prostate cancer on the population should warrant public health attention.
